Herpes zoster in psoriasis patients undergoing treatment with biological agents: prevalence, impact, and management challenges

References

• de la BrassinneMFaillaVNikkelsAFPsoriasis: state of the art 2013. Part I: clinical, historical, epidemiological and genetic aspects, co-morbidities and pathogenesisActa Clin Belg20136842743224635330
   PubMed Web of Science ®Google Scholar
• de la BrassinneMNikkelsAFPsoriasis: state of the art 2013. Part II: therapeuticsActa Clin Belg20136843344124635331
   PubMed Web of Science ®Google Scholar
• LeonardiCLPowersJLMathesonRTEtanercept Psoriasis Study GroupEtanercept as monotherapy in patients with psoriasisN Engl J Med2003349212014202214627786
   PubMed Web of Science ®Google Scholar
• ReichKNestleFOPappKEXPRESS Study InvestigatorsInfliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trialLancet200536694941367137416226614
   PubMed Web of Science ®Google Scholar
• GordonKBLangleyRGLeonardiCClinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension studyJ Am Acad Dermatol200655459860617010738
   PubMed Web of Science ®Google Scholar
• KimballABBensimonAGGuerinAEfficacy and safety of adalimumab among patients with moderate to severe psoriasis with co-morbidities: subanalysis of results from a randomized, double-blind, placebo-controlled, phase III trialAm J Clin Dermatol2011121515221110526
   PubMed Web of Science ®Google Scholar
• IsaacsDInfectious risks associated with biologicsAdv Exp Med Biol201376415115823654064
   PubMed Web of Science ®Google Scholar
• PereiraRLagoPFariaRTorresTSafety of anti-TNF therapies in immune-mediated inflammatory diseases: focus on infections and malignancyDrug Dev Res201576841942726482111
   PubMed Web of Science ®Google Scholar
• MurdacaGSpanòFContatoreMInfection risk associated with anti-TNF-α agents: a reviewExpert Opin Drug Saf201514457158225630559
   PubMed Web of Science ®Google Scholar
• GohLJewellTLaversuchCSamantaAA systematic review of the influence of anti-TNF on infection rates in patients with rheumatoid arthritisRev Bras Reumatol20135350151524477729
   PubMedGoogle Scholar
• CheHLukasCMorelJCombeBRisk of herpes/herpes zoster during anti-tumor necrosis factor therapy in patients with rheumatoid arthritis. Systematic review and meta-analysisJoint Bone Spine201481321522123932722
   PubMed Web of Science ®Google Scholar
• AdelzadehLJourabchiNWuJJThe risk of herpes zoster during biological therapy for psoriasis and other inflammatory conditionsJ Eur Acad Dermatol Venereol201428784685225081573
   PubMed Web of Science ®Google Scholar
• CacciapagliaFZuccaroCIannoneFVaricella-zoster virus infection in rheumatoid arthritis patients in the anti-tumour necrosis factor eraClin Exp Rheumatol201533691792326394271
   PubMed Web of Science ®Google Scholar
• GriffithsCEMStroberBEvan de KerkhofPACCEPT Study GroupComparison of ustekinumab and etanercept for moderate-to-severe psoriasisN Engl J Med2010362211812820071701
   PubMed Web of Science ®Google Scholar
• LangleyRGElewskiBELebwohlMERASURE Study GroupFIXTURE Study GroupSecukinumab in plaque psoriasis – results of two phase 3 trialsN Engl J Med2014714326338
   Web of Science ®Google Scholar
• ThaçiDBlauveltAReichKSecukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trialJ Am Acad Dermatol201573340040926092291
   PubMed Web of Science ®Google Scholar
• GordonKBBlauveltAPappKAUNCOVER-1 Study GroupUNCOVER-2 Study GroupUNCOVER-3 Study GroupPhase 3 trials of ixekizumab in moderate-to-severe plaque psoriasisN Engl J Med2016375434535627299809
   PubMed Web of Science ®Google Scholar
• BissonnetteRPariserDMWaselNRApremilast, an oral phosphodiesterase-4 inhibitor, in the treatment of palmoplantar psoriasis: results of a pooled analysis from phase II PSOR-005 and phase III efficacy and safety trial evaluating the effects of apremilast in psoriasis (ESTEEM) clinical trials in patients with moderate to severe psoriasisJ Am Acad Dermatol20167519910527021239
   PubMed Web of Science ®Google Scholar
• ArvinAMVaricella-zoster virusClin Microbiol Rev1996933613818809466
   PubMed Web of Science ®Google Scholar
• GershonAAGershonMDPathogenesis and current approaches to control of varicella-zoster virus infectionsClin Microbiol Rev201326472874324092852
   PubMed Web of Science ®Google Scholar
• GildenDNagelMACohrsRJVaricella-zosterHandb Clin Neurol201412326528325015490
   PubMedGoogle Scholar
• CDC [webpage on the Internet]Shingles (Herpes Zoster) Available from: www.cdc.gov/shinglesAccessed August 23, 2016
   Google Scholar
• NikkelsAFSadzot-DelvauxCPiérardGEAbsence of ICAM-1 expression in varicella zoster virus infected keratinocytes during herpes zoster. Another immune evasion strategy?Am J Dermatopathol200426273214726820
   PubMed Web of Science ®Google Scholar
• ArvinAMMoffatJFSommerMVaricella-zoster virus T cell tropism and the pathogenesis of skin infectionCurr Top Microbiol Immunol201034218920920397071
   PubMed Web of Science ®Google Scholar
• TreschSTruebRMKamarachevJFrenchLEHofbauerGFDisseminated herpes zoster mimicking rheumatoid vasculitis in a rheumatoid arthritis patient on etanerceptDermatology2009219434734919648728
   PubMed Web of Science ®Google Scholar
• WendlingDStreitGToussirotEPratiCHerpes zoster in patients taking TNFalpha antagonists for chronic inflammatory joint diseaseJoint Bone Spine200875554054318674945
   PubMed Web of Science ®Google Scholar
• McDonaldJRZeringueALCaplanLHerpes zoster risk factors in a national cohort of veterans with rheumatoid arthritisClin Infect Dis200948101364137119368499
   PubMed Web of Science ®Google Scholar
• StrangfeldAListingJHerzerPRisk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agentsJAMA2009301773774419224750
   PubMed Web of Science ®Google Scholar
• García-DovalIPérez-ZafrillaBDescalzoMABIOBADASER 2.0 Study GroupIncidence and risk of hospitalisation due to shingles and chickenpox in patients with rheumatic diseases treated with TNF antagonistsAnn Rheum Dis201069101751175520551153
   PubMed Web of Science ®Google Scholar
• SeracGTubachFMarietteXRisk of herpes zoster in patients receiving anti-TNF-α in the prospective French RATIO registryJ Invest Dermatol201213272672922113472
   PubMed Web of Science ®Google Scholar
• CurtisJRXieFYunHBernatskySWinthropKLReal-world comparative risks of herpes virus infections in tofacitinib and biologic-treated patients with rheumatoid arthritisAnn Rheum Dis Epub2016425
   Google Scholar
• YunHXieFDelzellERisks of herpes zoster in patients with rheumatoid arthritis according to biologic disease-modifying therapyArthritis Care Res (Hoboken)201567573173625201241
   PubMed Web of Science ®Google Scholar
• ZismanDBittermanHShalomGPsoriatic arthritis treatment and the risk of herpes zosterAnn Rheum Dis201675113113525261573
   PubMed Web of Science ®Google Scholar
• SeganJStaplesMPMarchLLassereMChakravartyEFBuchbinderRRisk factors for herpes zoster in rheumatoid arthritis patients: the role of tumour necrosis factor-α inhibitorsIntern Med J201545331031825565419
   PubMed Web of Science ®Google Scholar
• WinthropKLBaddleyJWChenLAssociation between the initiation of anti-tumor necrosis factor therapy and the risk of herpes zosterJAMA2013309988789523462785
   PubMed Web of Science ®Google Scholar
• LongMDMartinCSandlerRSKappelmanMDIncreased risk of herpes zoster among 108604 patients with inflammatory bowel diseaseAliment Pharmacol Ther201337442042923240738
   PubMed Web of Science ®Google Scholar
• FordACPeyrin-BirouletLOpportunistic infections with anti-tumor necrosis factor-α therapy in inflammatory bowel disease: meta-analysis of randomized controlled trialsAm J Gastroenterol201310812681276
   Web of Science ®Google Scholar
• DreiherJKreschFSComaneshterDCohenADRisk of herpes zoster in patients with psoriasis treated with biologicsJ Eur Acad Dermatol Venereol2012261127113221923837
   PubMed Web of Science ®Google Scholar
• FaillaVJacquesJCastronovoCNikkelsAFHerpes zoster in patients treated with biologicalsDermatology2012224325125622677775
   PubMed Web of Science ®Google Scholar
• Di CostanzoLAyalaFMegnaMGaudielloFPatrìABalatoNThe risk of herpes zoster in the anti-TNF-α era: a case report and review of the literatureJ Dermatol Case Rep2013711423580906
   PubMedGoogle Scholar
• StrangfeldAEveslageMSchneiderMTreatment benefit or survival of the fittest: what drives the time-dependent decrease in serious infection rates under TNF inhibition and what does this imply for the individual patient?Ann Rheum Dis201170111914192021791449
   PubMed Web of Science ®Google Scholar
• FaillaVNikkelsAFUstekinumab and herpes zosterDermatology2011222211912221266799
   PubMed Web of Science ®Google Scholar
• FaillaVCastronovoCMeexCNikkelsAFProtracted herpes zoster and severe postherpetic neuralgia after inadvertant infliximab administrationEur J Dermatol20112178278321700542
   PubMed Web of Science ®Google Scholar
• ZhuSMLiuYMAnEDChenQLInfluence of systemic immune and cytokine responses during the acute phase of zoster on the development of postherpetic neuralgiaJ Zhejiang Univ Sci B200910862563019650202
   PubMed Web of Science ®Google Scholar
• JavedSKamiliQUMendozaNTyringSKPossible association of lower rate of postherpetic neuralgia in patients on anti-tumor necrosis factor-αJ Med Virol201183112051205521915882
   PubMed Web of Science ®Google Scholar
• OxmanMNLevinMJJohnsonGRShingles Prevention Study GroupA vaccine to prevent herpes zoster and postherpetic neuralgia in older adultsN Engl J Med2005352222271228415930418
   PubMed Web of Science ®Google Scholar
• ZhangJXieFDelzellEAssociation between vaccination for herpes zoster and risk of herpes zoster infection among older patients with selected immune-mediated diseasesJAMA20123081434922760290
   PubMed Web of Science ®Google Scholar
• LalHCunninghamALGodeauxOZOE-50 StudyEfficacy of an adjuvanted herpes zoster subunit vaccine in older adultsN Engl J Med2015372222087209625916341
   PubMed Web of Science ®Google Scholar
• WernerRNNikkelsAFMarinovicBEuropean consensus-based guideline (S2K) on the management of herpes zoster. Part 2: treatmentJ Eur Acad Dermatol VenereolIn press
   Web of Science ®Google Scholar
• Nordgaard-LassenIDahlerupJFBelardEDanish Society for GastroenterologyGuidelines for screening, prophylaxis and critical information prior to initiating anti-TNF-alpha treatmentDan Med J2012597C448022759856
   PubMed Web of Science ®Google Scholar
• TranCTDucancelleAMassonCLunel-FabianiFHerpes zoster: risk and prevention during immunomodulating therapyJoint Bone Spine Epub2016527
   Web of Science ®Google Scholar
• NisarMKOstorAJTNF antagonists and shingles: is vaccination advisable?Ann Rheum Dis201372e123456927
   PubMed Web of Science ®Google Scholar
• WernerRNNikkelsAFMarinovicBEuropean consensus-based guideline (S2K) on the management of herpes zoster. Part 1: diagnostic meansJ Eur Acad Dermatol VenereolIn press
   Google Scholar
• El HayderiLBontemsSNikkels-TassoudjiNSatellite lesions accompanying herpes zoster: a new prognostic sign for high-risk zosterBr J Dermatol201517261530153425556958
   PubMed Web of Science ®Google Scholar